Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Orencia® (abatacept) – Expanded indication
October 30, 2023 - The FDA approved Bristol Myers Squibb’s Orencia (abatacept), for the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA).
